Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05901467 · ClinicalTrials.gov registry record · Phase 1
Recall by Genotype: Neuropeptide Stimulation
A Phase 1 study, sponsored by Stephanie B. Seminara, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05901467 is a Phase 1 study that was terminated before completion, run by Stephanie B. Seminara, MD. The registered enrollment target is 16 participants.
The verdict
NCT05901467, a Phase 1 study, was terminated before completion, sponsored by Stephanie B. Seminara, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective of this protocol is to assess response to kisspeptin and gonadotropin-releasing hormone (GnRH) stimulation testing as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals who carry variants in genes related to infertility.
Interventions
- DRUG kisspeptin 112-121
- DRUG GnRH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2024-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05901467
The ClinicalTrials.gov registry entry for NCT05901467 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephanie B. Seminara, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which kisspeptin 112-121 is the first listed.
NCT05901467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05901467 about?
NCT05901467 is a clinical study titled "Recall by Genotype: Neuropeptide Stimulation". The objective of this protocol is to assess response to kisspeptin and gonadotropin-releasing hormone (GnRH) stimulation testing as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals who carry variants in genes related to infertility.
What is the current status of trial NCT05901467?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-10-20. Estimated completion is 2024-05-29.
What interventions are being tested in trial NCT05901467?
The interventions under investigation include: kisspeptin 112-121 (DRUG), GnRH (DRUG).
Who is sponsoring clinical trial NCT05901467?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.